Malaria

WHO global antimalarial drug efficacy database

The WHO global antimalarial drug efficacy database was initiated in 2000 to centralize data collection and facilitate reporting on the status of antimalarial drug efficacy in malaria endemic countries. The contents of the database are extracted from published and non-published therapeutic efficacy studies conducted by ministries of health, national malaria control programmes, research institutes and NGOs. The database is the source for the antimalarial drug efficacy maps, the summary tables, and the Global report on antimalarial efficacy and drug resistance.

Antimalarial drug efficacy maps

The interactive maps of therapeutic efficacy study results provide a visual overview of the status of antimalarial drug efficacy in malaria endemic countries.

Summary tables on antimalarial drug efficacy

The most recent antimalarial drug efficacy data are summarized in the tables below. The summary tables provide treatment failure rates, grouped by treatment and country and sorted by WHO Region. All studies have a minimum follow-up of 28 days.

Therapeutic efficacy study results - P. falciparum
Therapeutic efficacy study results - P. vivax

Global report on antimalarial drug efficacy and resistance

The Global report, published once every five years, provides a comprehensive, global overview of antimalarial drug efficacy and the resistance of malaria parasites to antimalarial medicines during a five-year period. The next global report will be published in 2015.

Notes on data collection

Studies included in the database are conducted in accordance with the WHO standard protocol for monitoring antimalarial drug efficacy. Studies have a minimum follow-up of 28 days, with polymerase chain reaction (PCR)-correction to distinguish between treatment failures caused by reinfection from those caused by recrudescence.

Treatment failure rates are calculated using the per-protocol method. This analysis includes only patients who complete the entire study follow-up and have a clear outcome of either treatment success or failure. Patients who do not complete follow-up, deviate from the study protocol, or withdraw, are excluded from the analysis. Treatment failure rates using the Kaplan-Meier analysis are provided when available.

Since study duration often cross two calendar years, the year in the database refers to the year in which the study began.

Last update: 11 April 2014

Key documents

Share